Join us at MassBio’s Rare Disease Day on February 28 to hear from one of our rare disease development experts.
PRINCETON, NJ– Today, Certara®, the global leader in biosimulation, launches a new practice area dedicated to advancing rare disease drug development.
More than 7,000 rare diseases impact millions of people worldwide many of which have no treatment options. There are many challenges in developing treatments to address rare diseases, which includes poorly understood disease natural history, clinical endpoints which are not well defined, and small numbers of patients which make clinical trial design and execution challenging. In addition, regulatory and payer frameworks which provide opportunities for accelerated development, market access, and financial incentives remain underutilized.
Certara is uniquely positioned to offer solutions to drug development issues for our clients in this space, utilizing our cross-functional model-informed drug development capabilities. Many of Certara’s consultants have extensive experience working on rare diseases – which when brought together collectively can offer a powerful cross-functional service offering to advance these important development programs in collaboration with clients.
“Certara’s services and software have supported bringing more than 100 rare disease treatments to market. We want to ensure these patients receive the visibility and support needed to develop drugs that will improve their quality of living,” said Patrick Smith, Pharm.D, President of Integrated Drug Development at Certara.
Please join Certara at MassBio’s Rare Disease Day on February 28 at 10:00 am ET when Oxana Iliach, Ph.D., Senior Director, Regulatory Strategy and Policy, will participate in the Industry Panel: Expanding the Rare Disease View.
